Vabysmo is the only injectable eye medicine approved simultaneously in the US for wet AMD and DME, with flexible dosing regimens based on patient need
Acquisition will add GT005 to the Novartis portfolio, an investigational, one-time gene therapy currently in Phase 2 for the treatment of people living with Geographic atrophy
The implant is surgically inserted into the eye during a one-time, outpatient procedure and refilled every six months
Remote screening of diabetic retinopathy can help in early detection, even before there are any noticeable vision changes
It becomes the first ophthalmology biosimilar to gain FDA approval in the United States
Results from year two of the pivotal Phase 3 KITE clinical trial reaffirmed visual acuity gains and fluid reduction findings as well as safety profile from year one
Subscribe To Our Newsletter & Stay Updated
